Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine

被引:0
作者
Li Chen
Cai Cheng
Bicui Chen
Yue Zhao
Jiming Zhang
Bin Wang
机构
[1] Fudan University,Department of Pharmacy, HuaShan Hospital
[2] Fudan University,College of Pharmacy
[3] Fudan University,Department of Infectious Diseases, HuaShan Hospital
来源
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词
Telbivudine; Creatine kinase elevation; Cumulative incidence; Risk factors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:235 / 241
页数:6
相关论文
共 246 条
[1]  
Hadziyannis SJ(2012)Clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 167-185
[2]  
Vassilopoulos D(2008)Telbivudine in the treatment of chronic hepatitis B Expert Rev Gastroenterol Hepatol 2 13-22
[3]  
Caviglia GP(2015)Chronic hepatitis B therapy: available drugs and treatment guidelines Minerva Gastroenterol Dietol 61 61-70
[4]  
Abate ML(2009)Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Ther Clin Risk Manag 2009 789-798
[5]  
Pellicano R(2015)Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy J Hepatol 62 41-47
[6]  
Smedile A(2013)Lactic acidosis during telbivudine treatment for HBV: a case report and literature review World J Gastroenterol 19 5575-5580
[7]  
Osborn M(2009)2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486-495
[8]  
Marcellin P(2013)Dysphagia could be the first presenting symptom of telbivudine-induced myopathy Int Med J 43 1048-1049
[9]  
Wursthorn K(2012)Telbivudine myopathy in a patient with chronic hepatitis B Int J Clin Pharm 34 422-425
[10]  
Wedemeyer H(2013)Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B Clin Mol Hepatol 19 82-75